SPORE in Prostate Cancer

Publications

Found 70 results

Filters: First Letter Of Last Name is R [Clear All Filters]

2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

2018

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al.. 2018. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al.. 2018. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al.. 2018. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, R Karnes J, Ross AE, Schaeffer EM, Rubin MA et al.. 2018. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.. JCO Precis Oncol. 2018

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, R Karnes J, Ross AE, Schaeffer EM, Rubin MA et al.. 2018. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.. JCO Precis Oncol. 2018

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes J, Ross AE, Schaeffer EM, Rubin MA et al.. 2018. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes J, Ross AE, Schaeffer EM, Rubin MA et al.. 2018. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology.

Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga J, Palomero L, Farran-Matas S, Rubin MA, Shen MM et al.. 2018. NSD2 is a conserved driver of metastatic prostate cancer progression.. Nat Commun. 9(1):5201.

Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga J, Palomero L, Farran-Matas S, Rubin MA, Shen MM et al.. 2018. NSD2 is a conserved driver of metastatic prostate cancer progression.. Nat Commun. 9(1):5201.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Triscott J, Rubin MA. 2018. Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression? Cancer Discov. 8(6):682-685.

Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JMiguel, Chen Y, Rubin MA et al.. 2018. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.. J Clin Invest. 128(1):381-386.

Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JMiguel, Chen Y, Rubin MA et al.. 2018. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.. J Clin Invest. 128(1):381-386.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LLazo, Susani M et al.. 2018. Transcriptomic heterogeneity in multifocal prostate cancer.. JCI Insight. 3(21)

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LLazo, Susani M et al.. 2018. Transcriptomic heterogeneity in multifocal prostate cancer.. JCI Insight. 3(21)